World Innovation Lab

World Innovation Lab operates from Tokyo as a critical bridge between Silicon Valley and Japan, accelerating cross-border expansion for elite B2B SaaS and health tech platforms. The fund’s structure and partner network are explicitly designed to help US-headquartered companies enter the Japanese enterprise market and to help Japanese companies expand internationally. Healthcare exposure concentrates on AI/ML applications and health IT software.

The thesis is grounded in the observation that Japan represents a substantial enterprise market with structural characteristics that make entry difficult for foreign companies and that domestic Japanese companies frequently struggle to expand internationally without specialized support. World Innovation Lab is positioned to address both directions of that flow, providing capital and operational support to growth-stage companies for whom cross-border expansion is the primary strategic question. Healthcare investments under this thesis are typically B2B software companies, AI-driven enterprise tools, and health IT platforms with the operational maturity to manage international expansion.

The firm writes checks generally between $5M and $25M, operating at Series B, Series C, and growth stages. That stage focus means World Innovation Lab expects companies to have demonstrated product-market fit and credible commercial traction before engaging, with diligence calibrated to the growth-stage context. Geographically, the firm operates primarily in the Tokyo-Silicon Valley corridor, with selective participation in companies operating in other Asian or international markets.

The team is built around partners with deep operating and investment experience in both Japan and the US, including significant connections into the Japanese corporate, governmental, and venture ecosystems. That cross-border partner depth is structurally relevant for the firm’s thesis, since helping a US company enter Japan requires meaningful institutional access that is genuinely difficult to assemble independently. The team has experience supporting portfolio companies through significant cross-border milestones.

In working with companies, World Innovation Lab’s most distinctive value is its ability to facilitate Japanese market entry for US companies and international expansion for Japanese companies. That includes corporate partnership facilitation, regulatory and operational guidance, senior hiring across both geographies, and connections into the Japanese institutional investor base for subsequent rounds. For healthcare founders, the fit is strongest for those at growth stage with credible cross-border ambition, particularly between the US and Japan, where the firm’s specific expertise applies. The fit is weaker for early-stage companies still developing product-market fit or for those without a credible path to international expansion, since the firm’s mandate is calibrated to growth-stage cross-border outcomes. Founders considering World Innovation Lab should plan for an institutional process and should bring a clear articulation of how Japanese market entry or international expansion fits into their broader strategy.